Developmental biology

Resolve Biosciences Secures $71 Million Series B Financing to Accelerate Commercial Expansion to Meet Global Demand for Molecular Cartography™ Workflow

Retrieved on: 
Monday, October 24, 2022
Oncology, Health, Neurology, Research, Science, Biotechnology, Infection, Novo Nordisk Foundation Center for Protein Research, Disease, Vlaams Instituut voor Biotechnologie, German Cancer Research Center, Agriculture, Workflow, Laboratory, IT University of Copenhagen, Monheim am Rhein, Neuroscience, List of life sciences, DKFZ, Developmental biology, Investment, Partnership, Technology, University, Doctor of Philosophy, Cartography, Health, Neurology, Board, CEO, VIB, Resolve, DNA, COVID-19, Pathology, View, Medical imaging, Microscope, Genetics

Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced it has secured a $71 million Series B financing.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced it has secured a $71 million Series B financing.
  • Resolve intends to build on its successful commercial launch and use the proceeds from the financing to rapidly scale operations and accelerate product development to meet growing demand worldwide.
  • Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology.
  • Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

Trailhead Biosystems Raises $10 Million to Accelerate Growth

Retrieved on: 
Tuesday, October 11, 2022
Risk, Medicine, Therapy, Life, Multiple sclerosis, Machine learning, Biotechnology, Patient, 3D, Biology, Parkinson's disease, Research, Cell, Developmental biology, Drug discovery, IPSC, Doctor of Philosophy, Industry, Blood, Board, Alzheimer's disease, Brain, Robotics, Pancreas, Degenerative disease, Pharmaceutical industry, Fine chemical

CLEVELAND, Oct. 11, 2022 /PRNewswire/ -- Trailhead Biosystems Inc. (www.trailbio.com) - a biotechnology company pioneering the application of machine-enabled science towards understanding and controlling biology - announced completion of a $10 million Series A-2 equity financing. The company has developed revolutionary platform for generating specialized human cells for use in therapeutic cell development, drug discovery, organ-on-a-chip development, 3D organ printing, and human disease modeling. 

Key Points: 
  • "The need for specialized iPSC derived human cells is substantial," said Jan Jensen, PhD, Chief Executive Officer, and founder of Trailhead Biosystems.
  • "It is our goal to make any type of specialized human cell possible.
  • Trailhead's Quality-by-Design principles allow for the manufacturing of cells at scale, at a high-quality, and with less risk for research and development.
  • About Trailhead Biosystems: Trailhead Biosystems is pioneering the development of cell-based therapeutics using machine learning and bioinformatics.

Vizgen Unveils MERSCOPE™ Protein Co-detection Kit Enabling Simultaneous Imaging of Transcripts and Proteins in a Single Experiment

Retrieved on: 
Tuesday, September 20, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Neuroscience, Health, Efficiency, Developmental biology, Wyss Institute, Twitter, Infection, Coronavirus Scientific Advisory Board (Turkey), LinkedIn, Gene, Social media, Disease, CEO, Protein, Kit, Pathology, RNA-Seq, Organelle, Harvard Medical School, RNA, Genomics, Gene expression, Drug discovery, Microscope, Vaccine, Facebook

Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the launch of the MERSCOPE Protein Co-detection Kit, enabling subcellular spatial multi-omics measurement with the simultaneous detection of RNA and proteins during a standard MERFISH experiment.

Key Points: 
  • Vizgen , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the launch of the MERSCOPE Protein Co-detection Kit, enabling subcellular spatial multi-omics measurement with the simultaneous detection of RNA and proteins during a standard MERFISH experiment.
  • While RNA imaging can resolve the gene expression at a single cell level and help annotate the cell state in complex tissue, information such as cell morphology and pathological features can only be imaged by proteins.
  • The MERSCOPE Protein Stain Reagent Kit offers high quality protein staining, equivalent to that of protein immunofluorescence staining, and its oligo conjugated antibodies enable heightened detection of primary antibodies targeting proteins.
  • The companys MERSCOPE Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution.

Forsea Foods to focus on relieving bottleneck in seafood supply, starting with eel meat

Retrieved on: 
Tuesday, September 6, 2022
Hebrew University of Jerusalem, Eleazar Sukenik, Food, CEO, Strauss Group, Research, Doctor of Philosophy, Nachman, Electron, Bermuda Triangle, Eel, Tel Aviv University, Cell, Developmental biology, Medicine, Bioreactor, IIA, Organoid, Sargasso Sea, Kitchen, Meat, Seafood, Microplastics, Ecosystem, Taste, Bermuda, Environment, Mercury, Aquaculture, ForSea Ferries

ASHDOD, Israel, Sept. 6, 2022 /PRNewswire/ -- With the dawn of the cell-cultured seafood making waves, a new player has landed. FoodTech start-up Forsea Foods, Ltd. announces it has brought this novel concept closer to natural perfection through its patented organoid technology.

Key Points: 
  • FoodTech start-up Forsea Foods , Ltd. announces it has brought this novel concept closer to natural perfection through its patented organoid technology.
  • The start-up announces that it is kicking off its activities by targeting the supply gaps in the eel meat market.
  • Forsea claims that they will also yield the same nutritional profile as traditionally raised seafood.
  • While Forsea can cultivate practically any type of seafood, the company says it is currently focusing its efforts on cultivating the meat of freshwater eels.

Forsea Foods to focus on relieving bottleneck in seafood supply, starting with eel meat

Retrieved on: 
Tuesday, September 6, 2022
Hebrew University of Jerusalem, Eleazar Sukenik, Food, CEO, Strauss Group, Research, Doctor of Philosophy, Nachman, Electron, Bermuda Triangle, Eel, Tel Aviv University, Cell, Developmental biology, Medicine, Bioreactor, IIA, Organoid, Sargasso Sea, Kitchen, Meat, Seafood, Microplastics, Ecosystem, Taste, Bermuda, Environment, Mercury, Aquaculture, ForSea Ferries

ASHDOD, Israel, Sept. 6, 2022 /PRNewswire/ -- With the dawn of the cell-cultured seafood making waves, a new player has landed. FoodTech start-up Forsea Foods, Ltd. announces it has brought this novel concept closer to natural perfection through its patented organoid technology.

Key Points: 
  • FoodTech start-up Forsea Foods , Ltd. announces it has brought this novel concept closer to natural perfection through its patented organoid technology.
  • The start-up announces that it is kicking off its activities by targeting the supply gaps in the eel meat market.
  • Forsea claims that they will also yield the same nutritional profile as traditionally raised seafood.
  • While Forsea can cultivate practically any type of seafood, the company says it is currently focusing its efforts on cultivating the meat of freshwater eels.

Renown Cancer Expert Joins MetasTx’s Scientific Advisory Board

Retrieved on: 
Monday, August 29, 2022
Metastasis, CEO, Yale College, Cancer, Research, Fox Chase Cancer Center, Doctor of Philosophy, Precision medicine, Internal medicine, College, Half-life, Pittsburgh, National Science Advisory Board for Biosecurity, Institute of Cancer Research, Nobel Prize, MBA, Harvard University, Developmental biology, GLOBE, Mount Sinai School, Movement, Therapy, PAK, Advisory board, Institute, Biochemistry, Prostate cancer, Growth, Temple Health, Oncology, Pharmaceutical industry, Medical imaging, MD

On adding Dr. Chernoff to the Advisory Board, Harvey Homan, CEO and Co-Founder MetasTx commented, We are beyond pleased that Dr. Chernoff is joining our team.

Key Points: 
  • On adding Dr. Chernoff to the Advisory Board, Harvey Homan, CEO and Co-Founder MetasTx commented, We are beyond pleased that Dr. Chernoff is joining our team.
  • He then held a postdoctoral fellowship in cellular and developmental biology at Harvard University before joining Fox Chase Cancer Center.
  • For more information, visit www.metastx.com
    Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States.
  • Founded in 1904 in Philadelphia as one of the nations first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974.

Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin

Retrieved on: 
Friday, August 26, 2022
Nanotechnology, Patient, University, Technology, National Medal of Technology and Innovation, Allotransplantation, Mentorship, Research, AAAS Philip Hauge Abelson Prize, Sterilization, Cato, Engineering, Physics, Regenerative medicine, Administration, Tissue, Regeneration, Board, American Association for the Advancement of Science, RES, American Institute of Chemical Engineers, National, Goal, National Medal, American Institute, GLOBE, National academy, Developmental biology, Leadership, Rakesh Agrawal (chemical engineer), National Academy of Engineering, National Academy of Medicine, Cato T. Laurencin, Association, Invention, Philip Abelson, Â, Health, Walsh, Good tissue practice, American Association, Agriculture, Science

MARIETTA, Ga., Aug. 26, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today recognized Board Member, Cato T. Laurencin, M.D., Ph.D. for his leadership and contributions to advance the field of regenerative engineering. The Cato T. Laurencin Regenerative Engineering Founders’ Award has been established by the American Institute of Chemical Engineers (AIChE) Foundation and the AIChE Regenerative Engineering Society (RES) to recognize the accomplishments of individuals who have demonstrated leadership in the science and practice of convergence research as applied to regenerative engineering, a field pioneered by Dr. Laurencin.i The award additionally celebrates Dr. Laurencin’s impact on cultivating a more diverse and inclusive engineering and scientific community.

Key Points: 
  • This award celebrates his work and highlights the widespread impact and potential of researchers, educators, and mentors in this complex and emerging field.
  • MIMEDX is committed to promoting scientific innovation and translational research that advances regenerative medicine and its potential to improve peoples health.
  • The inaugural award will be presented in 2023 at the Regenerative Engineering Societys Annual Meeting.
  • Dr. Laurencin is internationally renowned for his work in biomaterials, stem cell science, nanotechnology, drug delivery systems, as well the field of regenerative engineering.

Regenerative Engineering Society Establishes Award in Honor of Founder Cato T. Laurencin

Retrieved on: 
Tuesday, August 9, 2022
National Medal of Technology and Innovation, American Institute of Chemical Engineers, Mentorship, Association, Philip Abelson, Chemical engineering, United, American Association, Nanotechnology, MiMedx, National, Laurencin, GLOBE, American Institute, American Association for the Advancement of Science, Cato, Leadership, White House, National academy, Tissue, Knowledge, Research, Government, Regeneration, Engineering, AAAS Philip Hauge Abelson Prize, White, Burroughs Wellcome Fund, Physics, National Medal, National Academy of Medicine, University, RE, Goal, National Academy of Engineering, Developmental biology, Administration, Pharmaceutical industry, Science

The Cato T. Laurencin Regenerative Engineering Founders Award will recognize the accomplishments of individuals who have demonstrated leadership in the science and practice of convergence research as applied to regenerative engineering a field pioneered by Dr. CatoT.

Key Points: 
  • The Cato T. Laurencin Regenerative Engineering Founders Award will recognize the accomplishments of individuals who have demonstrated leadership in the science and practice of convergence research as applied to regenerative engineering a field pioneered by Dr. CatoT.
  • The inaugural award will be presented in 2023 at the Regenerative Engineering Societys Annual Meeting.
  • In addition to establishing AIChEs Regenerative Engineering Society, Laurencin recently completed a term as an AIChE Board Director.
  • The Cato T. Laurencin Regenerative Engineering Society Founders Award will be presented to distinguished researchers, innovators, mentors, and teachers who have furthered the goals of this field.

Live Cell Imaging Global Market Expected to Reach $3.73 Billion in 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 5, 2022
Health, Technology, Photography, Genetics, Software, Biotechnology, Cell, Death, Cancer, Patient, Cros, Biotechnology, Protein, FRAP, Technology, Resonance, Growth, Application, Cellular, Photobleaching, HCS, FRET, Organization, Software, Cell biology, Incidence, Developmental biology, Drug discovery, Microscope, Lithium

The live-cell imaging market consists of sales of live cell imaging by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing and selling live cell imaging equipment and consumables.

Key Points: 
  • The live-cell imaging market consists of sales of live cell imaging by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing and selling live cell imaging equipment and consumables.
  • The rising incidence of cancer is expected to drive the growth of the live cell imaging market in the forecast period.
  • Global Live Cell Imaging Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    6.4.
  • Global Live Cell Imaging Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

Resolve Biosciences Sets New Standard for Single-Cell Spatial Analysis with Launch of Fully Automated Molecular Cartography™ Workflow

Retrieved on: 
Tuesday, June 7, 2022
Research, Infectious Diseases, Genetics, Biotechnology, Health, Agriculture, Natural Resources, Science, Oncology, Other Science, Inflammation Research, Â, Biomarker, Macrophage, Infection, German Resource Center for Genome Research, Doctor of Philosophy, Stanford University School of Medicine, Inflammation, Multimedia, Neurology, Technology, German Cancer Research Center, Research, Vlaams Instituut voor Biotechnologie, Gold, Tissue, View, Novo Nordisk Foundation Center for Protein Research, Observation, Agriculture, Lunch, Personalized medicine, CEO, List of life sciences, Center, Monheim am Rhein, B cell, Laboratory, Mouse, Molecular medicine, University of Copenhagen Nano-Science Center, Neuroscience, Cell, Liver, University, Patient, DNA, Steatosis, Science, Cartography, Disease, Fatty liver disease, VIB, Developmental biology, Pleasure, Systems biology, DKFZ, Medical imaging, Pharmaceutical industry, Microscope, Genetics, Genomics

Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the launch of its commercial Molecular Cartography workflow and the installation of the first systems at leading research institutions around the world.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography technology, today announced the launch of its commercial Molecular Cartography workflow and the installation of the first systems at leading research institutions around the world.
  • Previously, these customers accessed the power of the system through the companys commercial Molecular Cartography service offering and early access program.
  • Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of spatial biology.
  • Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.